Reviva Pharmaceuticals Holdings, Inc. Current Federal Tax Expense (Benefit)
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Current Federal Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-03-30
- Reviva Pharmaceuticals Holdings, Inc. current federal tax expense (benefit) for fiscal 2025 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. current federal tax expense (benefit) for fiscal 2024 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. current federal tax expense (benefit) for fiscal 2023 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. current federal tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 |
| 2023-12-31 | $0.00 10-K · filed 2025-04-03 |
| 2022-12-31 | $0.00 10-K · filed 2024-04-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |